Clinical trial · Interventional
Involvement of the Immune System in Intrinsic Radiosensitivity
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiotherapy is one of the major treatments for cancer. It may be indicated in more than two-thirds of patients, regardless of cancer location or disease stage. The mechanisms of radiotherapy action are numerous: halting tumor proliferation, inducing tumor cell death, triggering anti-tumor immune responses, and ensuring both local and systemic tumor control. As a result, current treatments are highly effective, providing, for instance, a 5-year overall survival rate of about 90%-95% for localized breast and prostate cancers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- TRANSPROUST is a prospective, single-center cohort.
- interventionNames
- Other: Blood samples
Primary outcomes (1)
- measure
- Identify immunological markers predictive of intrinsic radiosensitivity.
- timeFrame
- 48 hours
- description
- Identification of immunological markers predictive of intrinsic radiosensitivity using flow cytometry analysis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Patients who have been treated with radiotherapy * Absence of toxicity grade 2 or higher * Patients without psychiatric, sociological, family, or geographical difficulties that could interfere with patient compliance to the protocol or follow-up * Information and signed informed consent * Affiliated with social security Exclusion Criteria: * Inability to obtain patient consent * Patient refusing blood sample collection * Patient deprived of liberty or under legal protection (under guardianship, under curatorship) * Patients who have experienced radiation-induced toxicity of grade 2 or higher * Disease progression, relapse * Patient under State Medical Aid
References
Publications (0)
Data not yet available